41 results about "Gentamicin" patented technology

The invention belongs to the technical field of biology, and particularly relates to bifidobacterium longum subsp.infantis FMBL B250020GXY for metabolizing breast milk oligosaccharide and application of the bifidobacterium longum subsp.infantis FMBL B250020GXY, the bifidobacterium longum subsp.infantis FMBL B250020GXY is preserved in China Center for Type Culture Collection on September 1, 2025, and the preservation number is CCTCC M 20251931; three kinds of breast milk oligosaccharides, namely 2 '-fucosyllactose (2'-FL), lactose-N-neotetraose (LNnT) and lactose-N-tetraose (LNT), can be metabolized; plant source carbohydrates such as fructo-oligosaccharide and synanthrin can be metabolized; the compound has a relatively strong capability of removing DPPH and ABTS free radicals; a good inhibition effect is achieved on common pathogenic bacteria; good tolerance to acid and cholate is achieved; the strain is sensitive to gentamicin, streptomycin, tetracycline, chloramphenicol and vancomycin; the compound can be used for preparing antioxidant products, medicines for inhibiting pathogenic bacteria, infant foods and fermented foods, and has a wide application prospect.

The present invention discloses an IS26-based resistance gene control plasmid, engineering bacteria, bacterial agent and application, belonging to the technical field of genetic engineering. The nucleotide sequence of the IS26-based resistance gene control plasmid is shown in SEQ ID NO: 1 or SEQ ID NO: 2. The engineering bacteria and bacterial agent containing the resistance gene control plasmid can be used for the control of resistance genes. By specifically destroying the insertion sequence IS26, the number of resistance genes can be fundamentally reduced and the spread of resistance genes can be blocked, providing a precise solution for the treatment of drug resistance. It has broad-spectrum resistance bacteria control performance and can effectively control gentamicin, tetracycline, chloramphenicol and ampicillin-resistant bacteria in wastewater, with the highest control efficiency reaching 83.76%. The plasmid, engineering bacteria and bacterial agent have low preparation costs, can be used for in-situ treatment of wastewater, have low treatment costs and good effects, and have broad application prospects.

The invention belongs to the technical field of veterinary drugs, and discloses a Chinese pulsatilla root alcohol extract and gentamicin composition and application thereof in inhibition of drug-resistant salmonella typhimurium. The pulsatilla alcohol extract composition provided by the invention comprises pulsatilla alcohol extract and gentamicin, and for salmonella typhimurium, the optimal ratio concentration of the pulsatilla alcohol extract to the gentamicin is 31.25 mg / mL: 2 [mu] g / ml; the Chinese pulsatilla root alcohol extract and the gentamicin have the synergistic bacteriostatic effect on salmonella typhimurium, the composition reduces the concentration of single bacteriostasis of the Chinese pulsatilla root alcohol extract and the gentamicin, the cost is saved, and the composition has wide application prospects and development value in the fields of food processing, medicine and breeding industry.

The application discloses application of antibacterial peptide BMAP-28 and antibiotics in combined preparation of antibacterial drugs and belongs to the technical field of biological medicine. The antibiotics are selected from one or more of the following: ciprofloxacin, gentamicin and cefixime. The application combines the antibacterial peptide BMAP-28 with antibiotics such as ciprofloxacin and gentamicin, finds that the combination has a significant synergistic antibacterial effect on Enterobacter sakazii, can greatly save the dosage of the drug, reduce the toxic side effect and block the evolution process of drug resistance. Through the destruction of the bacterial cell membrane and the assistance of the antibiotic effect, the combination can effectively overcome the multiple drug resistance, widen the antibacterial spectrum and has a wide clinical application prospect.

The invention discloses an anti-GM antibody and application thereof, and relates to the technical field of antibiotic residue immunoassay. Wherein the anti-GM antibody, namely an anti-gentamicin antibody, is targeted to a gentamicin (GM) antigen epitope, and the anti-GM antibody, namely the anti-gentamicin antibody, is targeted to a gentamicin (GM) antigen epitope; the gene comprises HCDR1, HCDR2 and HCDR3 of which the amino acid sequences are shown as SEQ ID No.1, 2 and 3 and / or LCDR1, LCDR2 and LCDR3 of which the amino acid sequences are shown as SEQ ID No.4, 5 and 6, and is specifically combined with a gentamicin antigen epitope by virtue of the HCDR1, the HCDR2 and the LCDR3. The invention also discloses polynucleotide for coding the gene and a kit / non-diagnostic method related to the polynucleotide, application and the like. Compared with the prior art, the anti-GM antibody can be highly specifically combined with a gentamicin epitope, and no cross reaction exists; the polynucleotides, kits / non-diagnostic methods, applications and the like are also beneficial to rapid and accurate screening of gentamicin residues in a sample.

Among hospital–acquired infections, Pseudomonas aeruginosa-associated urinary tract infections (UTIs) are mainly caused by indwelling urethral catheters (catheter-associated UTIs or CAUTIs) and are difficult to treat, resulting in high rates of morbidity among hospitalized patients. While antibiotics can successfully treat bacteria in the bladder lumen, they are inefficient at crossing stratified urothelium plasma membranes to kill persistent intracellular bacterial communities (IBCs). Herein, UTI IBCs are targeted by locally delivering the antibiotic gentamicin and / or the steroid hormone estradiol via polymeric nanogels conjugated with a cell-penetrating peptide Cys-Gly-Lys-Arg-Lys (CGKRK - SEQ ID NO:1). This approach delivered more intracellular gentamicin compared to drug delivered in solution in vitro and more estradiol compared to conventional methods. In an acute UTI murine model, the nanogel cell-penetrating peptide drug delivery system facilitated the transport of gentamicin into the urothelium and resulted in > 90% clearance of a uropathogenic P. aeruginosa clinical strain in vivo.

The present application belongs to the technical field of biological bionics, polymer, hydrogel material and the like, and particularly relates to a preparation method of a porous surface fracture internal fixation plate. The gentamicin-chitosan-acetic acid mixed solution is placed in an air compressor, the porous surface of the 3D printed fracture internal fixation plate is sprayed, after completion, the calcium chloride-collagen mixed solution is sprayed, then the fracture internal fixation plate is immersed in sodium hydroxide solution and sodium carbonate solution in sequence, and then freeze-drying is performed, so that the mussel shell bionic porous surface fracture internal fixation plate is obtained. The fracture internal fixation plate obtained by the present application has good biocompatibility, stable performance, mechanical properties close to natural bone and can realize drug loading for local prevention of fracture infection.

The invention discloses antibiotic-loaded in-situ modified platelet-rich fibrin gel as well as a preparation method and application thereof. The antibiotic-loaded in-situ modified platelet-rich fibrin gel is prepared from the following components in percentage by mass: 88 to 92 percent of PRF (platelet-rich fibrin) matrix, 5 to 8 percent of antibiotic and 3 to 4 percent of modifier, the PRF matrix comprises platelets, leukocytes and fibrin, the antibiotic is vancomycin or gentamicin, and the modifier is a zinc ion-containing compound or quaternized chitosan. The gel can be applied to preparation of chronic infection wound dressing, the antibiotic loading rate of the gel is increased, the gel has the slow release characteristic, the accumulative release within 7 days is 82.3 + / -5.6%, the burst release within 24 hours is less than 15%, the wound healing speed is increased by 40%, and the biological membrane clearance rate is 100%.

The invention discloses a fixing material for a medical device implant and a preparation method of the fixing material. The fixing material comprises a degradable polymer base material with a porous structure and a drug sustained-release coating uniformly loaded on the degradable polymer base material, holes in the degradable polymer are uniformly distributed in a staggered array manner, the holes are circular, the aperture of each hole is 0.5-3.0 mm, and the distance between every two adjacent holes is 0.5-3.0 mm; the drug sustained-release coating contains antibiotics; the antibiotics comprise rifampicin, minocycline hydrochloride, vancomycin, tobramycin, gentamicin and the like. The fixing material disclosed by the invention takes the degradable polymer as a base material, and the drug-loading coating containing antibiotics and anti-inflammatory substances is loaded on the surface, so that slow release of antibiotic drugs can be realized, and the fixing material has excellent antibacterial and anti-inflammatory performance and complete absorbability in a biological environment; and the problems of biocompatibility, infection risk and secondary operation removal of the implant for a long time are solved.

The invention discloses D-type mannosylerythritol lipid as well as a preparation method and application thereof. According to the invention, the green and bio-friendly D-type mannosylerythritol lipid is used as a biological bacteriostatic agent and is independently used or combined with other bacteriostatic agents (cefaclor, gentamicin or erythromycin and the like); effective inhibition and even killing of various pathogenic microorganisms (methicillin-resistant staphylococcus aureus, bacillus subtilis or bacillus cereus and the like) are realized. The novel bacteriostatic strategy of the D-type mannosylerythritol lipid provided by the invention not only can effectively realize efficient bacteriostasis, reduce the dosage of an antibacterial agent and reduce the graded bacteriostatic concentration index to 0.09, but also shows good biocompatibility, has a therapeutic index as high as 44.81, and has a wide application prospect.

The invention relates to the technical field of microbiological detection, in particular to a method for detecting clostridium in cosmetics. The invention provides a modified reinforced clostridium culture medium, a modified Columbia agar culture medium and a method for detecting clostridium in cosmetics, and the method is specifically as follows: the modified reinforced clostridium culture medium can inhibit the activity of preservatives in the cosmetics and improve the clostridium detection rate by adding Tween 80, lecithin and sodium thiosulfate; according to the modified Columbia agar culture medium, polymyxin B and gentamicin in a specific proportion are added, so that interference of non-target bacteria can be effectively inhibited, and detection specificity is enhanced. Based on the two modified culture media, the detection method established by the invention adopts a sample preparation mode of normal temperature and heating dual-condition treatment, and the detection rate of target bacteria can be remarkably improved. The method has the advantages of rapidness, high efficiency, high specificity, high detection rate, low cost, simplicity and convenience in operation and the like, and is particularly suitable for rapid screening requirements of supervision departments and detection mechanisms.

The invention belongs to the technical field of microorganisms, and particularly relates to lactobacillus johnsonii with a function of resisting multiple drug-resistant bacterium biological membranes and anti-inflammatory activity and application of the lactobacillus johnsonii. The lactobacillus johnsonii A25041 provided by the invention has strong inhibition and anti-biofilm activity on multi-drug-resistant gram-negative bacteria (including escherichia coli, pseudomonas aeruginosa and acinetobacter baumannii) and methicillin-resistant staphylococcus aureus, and the lactobacillus johnsonii A25041 has good acid-base tolerance and gastrointestinal fluid tolerance, so that the lactobacillus johnsonii A25041 can be used for preparing medicines for preventing and treating various diseases. The composition shows excellent anti-inflammatory activity and oxidation resistance, does not have hemolysis capacity, is good in safety, has natural drug resistance to gentamicin, tetracycline, ciprofloxacin, lincomycin and compound sulfamethoxazole, can be used together with antibiotics at the same time or in sequence, maintains intestinal microecological balance and relieves antibiotic burden while exerting the sterilization effect of the antibiotics, and has a good application prospect. The method can be widely applied to functional food development, and has important application value in the field of biological medicine and daily chemical products.

The invention relates to the technical field of organic chemistry, and particularly discloses an isoxazole amide derivative with a structure shown in a general formula III as well as a preparation method and application of the isoxazole amide derivative. The isoxazole amide derivative disclosed by the invention shows remarkable antibacterial activity on staphylococcus aureus, escherichia coli, methicillin-resistant staphylococcus aureus (MRSA) and fluoroquinolone-resistant escherichia coli (FREC), the activity of part of compounds is superior to that of gentamicin, and the isoxazole amide derivative has broad-spectrum antibacterial potential and can be used for preparing medicines for treating related bacterial infections.

The present invention belongs to the field of antimicrobial peptides, and specifically relates to an antimicrobial peptide, antimicrobial product and application that inhibits a variety of human pathogens. The antimicrobial peptide is named CAMP1229NC, and is obtained by capping the polypeptide shown in SEQ ID NO:1 with an N-terminal acetyl group and a C-terminal amino group. The antimicrobial peptide exhibits significant antibacterial activity against Staphylococcus aureus standard strain ATCC12600, Pseudomonas aeruginosa PAO1, Klebsiella pneumoniae, Acinetobacter baumannii standard strain ATCC19606, methicillin-resistant Staphylococcus aureus ATCC33591, methicillin- and gentamicin-resistant Staphylococcus aureus ATCC33592 and Acinetobacter baumannii bio-53272 resistant to multiple antibiotics, effectively overcoming the limitations of traditional antimicrobial peptides.

The application discloses an anti-GM antibody and application thereof, and relates to the technical field of antibiotic residue immunoassay. The anti-GM antibody, i.e. an anti-gentamicin antibody, targets a gentamicin (GM) antigen epitope; the anti-GM antibody comprises HCDR1, HCDR2, HCDR3 with an amino acid sequence as shown in SEQ ID No. 1, 2, 3 and / or LCDR1, LCDR2, LCDR3 with an amino acid sequence as shown in SEQ ID No. 4, 5, 6, and specifically binds to the gentamicin antigen epitope. The application further discloses polynucleotides encoding the anti-GM antibody and a kit / non-diagnostic method and application related to the anti-GM antibody. Compared with the prior art, the anti-GM antibody can highly specifically bind to the gentamicin antigen epitope without cross-reaction; and the polynucleotides, the kit / non-diagnostic method and the application are also beneficial to rapid and accurate screening of gentamicin residues in samples.

The invention relates to the technical field of assisted reproduction, in particular to a sperm gradient separating medium and a preparation method and application thereof. The sperm gradient separation liquid comprises a gradient liquid A and a gradient liquid B; the gradient solution A and the gradient solution B comprise sodium chloride, potassium chloride, magnesium sulfate, monopotassium phosphate, calcium chloride, sodium pyruvate, glucose, gentamicin, a sodium lactate solution, 4-hydroxyethylpiperazine ethanesulfonic acid, sodium bicarbonate, human serum albumin, progesterone and Percoll PLUS; the Percoll PLUS mass concentration of the gradient solution A is 70 to 85 percent; the Percoll PLUS mass concentration of the gradient solution B is 35 to 45 percent; the mass ratio of sodium chloride to potassium chloride to magnesium sulfate to calcium chloride in the gradient solution A to the gradient solution B is (5-5.5): (0.3-0.38): (0.25-0.30): (0.24-0.28); the mass ratio of the human serum albumin to the progesterone in the gradient solution A to the gradient solution B is (3-7): (0.00075-0.00085). The sperm gradient separation liquid can improve the activity of forward sperms after treatment, the activity of sperms after treatment, the recovery rate of active sperms and the improvement rate of sperm activity.

The invention provides nitrate reducing bacteria C381 as well as a method and application thereof. The nitrate reducing bacteria C381 is preserved in China General Microbiological Culture Collection Center (CGMCC), and the preservation number is CGMCC No.36842; the invention provides a novel oral cavity probiotic nitrate reducing bacteria C381, the nitrate reducing bacteria C381 has an inhibition effect on periodontal disease bacteria, and the nitrate reducing bacteria C381 is sensitive to antibiotics such as erythromycin, piperacillin, minocycline, doxycycline, cefazolin, tetracycline, amikacin, gentamicin, vancomycin and cefoperazone, and can be used for preparing oral cavity probiotics for treating periodontal disease bacteria. And the product has good survival ability in the oral cavity.

The present invention belongs to the field of antimicrobial peptides, and specifically relates to an antimicrobial peptide, antimicrobial product and application with a broad-spectrum antimicrobial effect. The antimicrobial peptide is named CAMP502NC, and is obtained by capping the polypeptide shown in SEQ ID NO:1 with an N-terminal acetyl group and capping the C-terminal amino group. The antimicrobial peptide exhibits significant antimicrobial activity against Staphylococcus aureus standard strain ATCC12600, Pseudomonas aeruginosa PAO1, Klebsiella pneumoniae, Acinetobacter baumannii standard strain ATCC19606, methicillin-resistant Staphylococcus aureus ATCC33591, methicillin- and gentamicin-resistant Staphylococcus aureus ATCC33592 and Acinetobacter baumannii bio-53272 resistant to multiple antibiotics, effectively overcoming the limitations of traditional antimicrobial peptides.

The utility model relates to the technical field of medical rivets, and provides an antibacterial absorbable gentamicin-loaded silk fibroin medical rivet and a mold. The rivet rod of the rivet is provided with an inner hexagonal notch and a wire passing through hole, and the screw pitches of threads at the near end and the far end of the rivet are different, so that the fixing strength of the rivet in sclerotin can be enhanced; the material overcomes the defects that metal cannot be absorbed and polylactic acid is used as a material, and can be degraded in time, resist bacteria, reduce foreign body reaction and inflammation and promote tissue healing; and the internal structural design of the rivet can meet the use requirement of the rivet under an arthroscopic surgery. The personalized mold is suitable for the special preparation process of fibroin, a mold body is composed of an upper mold body and a lower mold body which are detachable, and a pouring cavity formed by butt joint of pouring grooves of the upper mold body and the lower mold body can precisely mold the appearance of a rivet; the inner core assembly comprises an inner hexagonal column, a circular column and a positioning seat, and the inner structure of the rivet can be accurately formed. And the rivet is integrally formed to avoid later processing, so that high standard and consistency of products are ensured. The mold is ingenious in overall matching, convenient to assemble, maintain and operate, and time-saving and labor-saving.

The invention provides bacillus C367 as well as a method and application thereof. The bacillus C367 is preserved in the China General Microbiological Culture Collection Center (CGMCC), and the preservation number is CGMCC No.36841; the bacillus C367 is separated from the Inner Mongolia cheese; the bacillus C367 can be used for preparing medicines for treating or preventing periodontal diseases; the invention provides a novel oral cavity probiotic bacillus C367, the bacillus C367 has an inhibition effect on periodontal disease bacteria, and the bacillus C367 is sensitive to antibiotics such as minocycline, amikacin, tetracycline, erythromycin, cefoperazone, streptomycin, kanamycin, gentamicin, vancomycin and ceftriaxone, and has good survival ability in an oral cavity.

The present invention belongs to the field of antimicrobial peptides, and specifically relates to an antimicrobial peptide, antimicrobial product and application with a broad-spectrum antibacterial effect. The antimicrobial peptide is named CAMP1111NC, and is obtained by capping the polypeptide shown in SEQ ID NO:1 with an N-terminal acetyl group and a C-terminal amino group. The antimicrobial peptide exhibits significant antimicrobial activity against Staphylococcus aureus standard strain ATCC12600, Pseudomonas aeruginosa PAO1, Klebsiella pneumoniae, Acinetobacter baumannii standard strain ATCC19606, methicillin-resistant Staphylococcus aureus ATCC33591, methicillin- and gentamicin-resistant Staphylococcus aureus ATCC33592 and Acinetobacter baumannii bio-53272 resistant to multiple antibiotics, effectively overcoming the limitations of traditional antimicrobial peptides.

The invention discloses tetragenococcus halophilus and an application thereof. The preservation number of the tetragenococcus halophilus is GDMCC (China General Microbiological Culture Collection Center) 66036, and the preservation number of the tetragenococcus halophilus is CGMCC 66036. The tetracoccus halophilus is sensitive to eight antibiotics such as ampicillin, gentamicin and kanamycin, does not have drug-resistant genes and virulence genes, and can generate functional active substances with higher levels, such as protocatechuic acid, hydroxyphenyllactic acid, phenyllactic acid, 4-(methylthio)-2-butanol and 3-indoleacrylic acid. The tetracoccus halophilus has high capacity of generating volatile flavor substances and can be used for improving flavor characteristics of the fermented soybean paste, and the fermented soybean paste prepared by fermentation of the tetracoccus halophilus has rich ester fragrance, high sweet and delicious taste and low bitter aftertaste. The fermented soybean paste prepared by fermentation of the tetragenococcus halophilus has a relatively high level of free amino acid content, especially sweet and delicious free amino acids, and also has a relatively high level of succinic acid and malic acid content.

The invention belongs to the field of antibacterial peptides, and particularly relates to an antibacterial peptide for inhibiting various human pathogenic bacteria, an antibacterial product and application. The antibacterial peptide is named as CAMP1229NC, and is obtained by performing N-terminal acetyl end capping and C-terminal amino end capping on polypeptide shown in SEQ ID NO: 1. The antibacterial peptide has remarkable antibacterial activity on a staphylococcus aureus standard strain ATCC12600, pseudomonas aeruginosa PAO1, klebsiella pneumoniae, an acinetobacter baumannii standard strain ATCC19606, methicillin-resistant staphylococcus aureus ATCC33591, methicillin-resistant and gentamicin-resistant staphylococcus aureus ATCC33592 and acinetobacter baumannii bio-53272 resistant to various antibiotics, and the antibacterial peptide can be used for preparing the antibacterial peptide. The limitation of the traditional antibacterial peptide is effectively overcome.

The invention belongs to the technical field of stem cell culture, and particularly relates to a preparation method of umbilical cord mesenchymal stem cells. Comprising the following steps: placing a collected umbilical cord in a collection solution, preserving at 2-8 DEG C for 66-78h, then taking out the umbilical cord, cutting the umbilical cord into blocks, inoculating the obtained tissue blocks into a T75 cell culture bottle, inversely incubating the tissue blocks, then adding a culture medium for culturing, and carrying out passage when the cell fusion degree reaches 90%. The collecting liquid is prepared from 6 g / L to 10 g / L of sodium chloride, 0.3 g / L to 0.5 g / L of potassium chloride, 0.5 g / L to 2 g / L of glucose, 0.02 g / L to 0.03 g / L of gentamicin, 0.5 g / L to 2 g / L of human serum albumin, 0.02 g / L to 0.03 g / L of transferrin and the balance water. The umbilical cord is preserved by adopting the self-made collection liquid, so that the preservation time of the umbilical cord is prolonged, and the activity of the umbilical cord is enhanced. Meanwhile, according to the preparation method, the separation process of the MSC is optimized, and the separation efficiency and the number of obtained cells are improved.

N-Functionalized Indole Compounds as Antimicrobial Agents and Process for Preparation Thereof The present invention relates to novel N-functionalized indole compounds and their synthesis using ionic liquids as green reagents and / or solvents in a two to four-step process. The compounds exhibit potent antibacterial activity against multi-drug resistant and susceptible gram-positive bacteria, including Staphylococcus aureus and Enterococcus sp. Synergistic effects are observed when combined with gentamicin or levofloxacin, including activity against resistant MRSA (NRS 119). In-vivo efficacy is demonstrated in a murine skin infection model via topical and oral administration.

An antimicrobial composition comprising an antimicrobial compound and a population of metal nanoparticles is provided. The antimicrobial compound is preferably an antibiotic. The metal nanoparticle may comprise silver and / or copper and may also comprise a polymer coating such as poly(N-vinylpyrrolidone). The antimicrobial composition wherein the population of silver nanoparticles is formed by (a) mixing a first aqueous alkaline solution with an aqueous polymer solution to form an aqueous polymer solution; and (b) mixing the aqueous alkaline polymer solution with an aqueous solution of a metal salt to form a solution of polymer-coated metal nanoparticles is provided. A coating or treatment for a surface or substrate comprising the antimicrobial composition is provided. A medical device comprising the coating or treatment is provided. The medical device may be a wound care dressing or a bandage. A silver nanoparticle coated with poly(N-vinylpyrrolidone) is exemplified. Combinations of the PVP-coated silver nanoparticles (AgNP) and various antibiotics were tested. Compositions comprising silver nanoparticles and aminoglycosides, such as kanamycin and gentamicin, were particularly effective. A combination of silver nanoparticles and ebselen was also particularly effective against E. coli and S. aureus.

The invention provides application of ferulic acid and antibiotics in preparation of a synergistic antibacterial agent for escherichia coli O157: H7, and belongs to the technical field of antibacterial agents. The invention firstly provides an application of ferulic acid in preparation of a medicine for resisting a biofilm inhibitor, and provides an application of ferulic acid and antibiotics in preparation of a synergistic antibacterial medicine for escherichia coli O157: H7 based on the application. The invention proves that ferulic acid (FA) shows remarkable biofilm activity resistance, extracellular polymeric substance (EPS) inhibition capability and motility interference effect on the premise of not influencing the growth of escherichia coli. More importantly, when the FA is combined with clinically common antibiotics such as fosfomycin, ceftriaxone, gentamicin, tetracycline and the like, a synergistic antibacterial effect is shown, so that the FA not only has the intrinsic biofilm resistance, but also can be used as an antibiotic adjuvant, and a novel combined treatment strategy is provided for escherichia coli infection.

The invention discloses application of BSA (Bovine Serum Albumin) in improving the performance of low-density boar semen, and the BSA is particularly suitable for 0.5 billion / 60ml low-density boar semen. Accordingly, the inventor also develops a boar semen diluent, which comprises a basic solution, a nutritional agent, a buffer agent and an electrolyte, and also comprises a core film protecting agent, an antioxidant and a composite antibacterial agent, the core film protecting agent is BSA, the nutritional agent is composed of glucose and fructose, the antioxidant is composed of glutathione and arbutin, and the composite antibacterial agent is composed of penicillin, streptomycin and gentamicin. By accurately optimizing the BSA addition concentration and cooperating with glucose and fructose (dual-energy supply), a high-quality sperm protection microenvironment system of'targeted film protection-environment stabilization-energy supply 'is constructed, the problems of short preservation time and poor sperm form integrity when low-density sperms are treated by conventional diluents are solved, and cost reduction and efficiency improvement of large-scale pig farms can be realized.

The invention discloses a tri-modal antibacterial hydrogel dressing as well as a preparation method and application thereof, and belongs to the technical field of biological materials. The three-mode antibacterial hydrogel dressing disclosed by the invention is a composite PVA / QCS / TZG hydrogel dressing; the composite PVA / QCS / TZG hydrogel dressing is prepared by a one-pot method. In the composite PVA / QCS / TZG hydrogel dressing, the mass fraction of the QCSd is 5.25 wt% to 7.25 wt%, and the mass fraction of the TZG NPs is 6.25 wt% to 31.25 wt%. The composite PVA / QCS / TZG hydrogel dressing is prepared through a simple one-pot method, the production method is simple, no cross-linking agent with toxic hidden danger is needed, and the environmental friendliness is high; according to the hydrogel dressing prepared by the invention, a triple sterilization mode consisting of QCS contact killing, Zn < 2 + > destroying and gentamicin eradication is established.

The invention belongs to the technical field of biological medicines, and particularly relates to application of oxaloacetic acid in preparation of a medicine for enhancing sensitivity of pathogenic bacteria to gentamicin. It is found for the first time that oxaloacetic acid can significantly improve the sensitivity of pathogenic bacteria to antibiotics, and oxaloacetic acid and antibiotics are combined to prepare the anti-pathogenic-bacterium medicine. The compound has a good killing effect on gram-positive bacteria including staphylococcus aureus and listeria monocytogenes and gram-negative bacteria including edwardsiella tarda, pseudomonas aeruginosa and aeromonas hydrophila, and the compound has a good killing effect on gram-positive bacteria including staphylococcus aureus and listeria monocytogenes and gram-negative bacteria including edwardsiella tarda, pseudomonas aeruginosa and aeromonas hydrophila. Combination of oxaloacetic acid and antibiotics has good application value and significance in production and development of anti-pathogenic bacteria drugs.